8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Mar 5, 2026·SEC
Lifecore Biomedical, Inc.(LFCR)Earnings, Financials & Key Ratios
LFCR•NASDAQ
$4.77
$179M mkt cap·Price updated May 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryContract development and manufacturing services
AboutLifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.Show more
- Revenue$129M+0.5%
- EBITDA-$9M-992.2%
- Net Income-$39M-422.3%
- EPS (Diluted)-1.27-484.8%
- Gross Margin31.27%-4.2%
- EBITDA Margin-7.15%-987.1%
- Operating Margin-13.38%-94.1%
- Net Margin-30.04%-420.8%
- ROE-612.08%-280.5%
- ROIC-9.94%-69.1%
- Debt/Equity97.92+729.5%
- Interest Coverage-0.77-150.5%
LFCR Key Insights
Lifecore Biomedical, Inc. (LFCR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 5.0% through buybacks
✗Weaknesses
- ✗High debt to equity ratio of 97.9x
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 124.3x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LFCR Price & Volume
Lifecore Biomedical, Inc. (LFCR) stock price & volume — 10-year historical chart
Loading chart...
LFCR Growth Metrics
Lifecore Biomedical, Inc. (LFCR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-13.34%
5 Years-4.24%
3 Years5.02%
TTM3.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.66%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM30.72%
Return on Capital
10 Years-4.01%
5 Years-6.64%
3 Years-8.73%
Last Year-8.13%
LFCR Recent Earnings
Lifecore Biomedical, Inc. (LFCR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 6, 2026EPS
$0.43
Est $0.29
-48.3%
Revenue
$23M
Est $26M
-10.6%
Q2 2026
Mar 16, 2026EPS
$0.16
Est $0.29
+44.8%
Revenue
$35M
Est $33M
+6.1%
Q4 2025
Nov 6, 2025EPS
$0.29
Est $0.30
+3.3%
Revenue
$31M
Est $26M
+17.5%
Q3 2025
Aug 7, 2025EPS
$0.10
Est $0.09
-11.1%
Revenue
$36M
Est $25M
+44.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.43vs $0.29-48.3% | $23Mvs $26M-10.6% |
| Q2 2026 | Mar 16, 2026 | $0.16vs $0.29+44.8% | $35Mvs $33M+6.1% |
| Q4 2025 | Nov 6, 2025 | $0.29vs $0.30+3.3% | $31Mvs $26M+17.5% |
| Q3 2025 | Aug 7, 2025 | $0.10vs $0.09-11.1% | $36Mvs $25M+44.3% |
Based on last 12 quarters of dataView full earnings history →
LFCR Peer Comparison
Lifecore Biomedical, Inc. (LFCR) competitors in Contract development and manufacturing services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PCRX | 929.88M | 23.64 | 147.75 | 3.63% | 1.27% | 1.31% | 0.66 | |
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 ATRC | 1.41B | 27.80 | -115.83 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 ALGN | 12.06B | 168.39 | 29.80 | 0.9% | 10.5% | 10.7% | 0.03 | |
 MMSI | 3.72B | 62.33 | 29.26 | 11.66% | 9.03% | 8.95% | 0.57 |
Compare LFCR vs Peers
Lifecore Biomedical, Inc. (LFCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LFCR Income Statement
Lifecore Biomedical, Inc. (LFCR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | May'17 | May'18 | May'19 | May'20 | May'21 | May'22 | May'23 | May'24 | May'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 532.26M | 524.23M | 557.56M | 160.07M | 100.87M | 111.27M | 103.27M | 128.26M | 128.87M | 135.16M |
| Revenue Growth % | -1.63% | -1.51% | 6.36% | -71.29% | -36.98% | 10.31% | -7.19% | 24.2% | 0.47% | 3.72% |
| Cost of Goods Sold | 449.07M | 445.89M | 476.56M | 120.68M | 61.94M | 72.2M | 75.28M | 86.41M | 88.57M | 93.03M |
| COGS % of Revenue | 84.37% | 85.06% | 85.47% | 75.39% | 61.4% | 64.89% | 72.9% | 67.37% | 68.73% | - |
| Gross Profit | 83.19M▲ 0% | 78.34M▼ 5.8% | 81M▲ 3.4% | 39.39M▼ 51.4% | 38.94M▼ 1.1% | 39.07M▲ 0.3% | 27.98M▼ 28.4% | 41.85M▲ 49.5% | 40.3M▼ 3.7% | 42.13M▲ 0% |
| Gross Margin % | 15.63% | 14.94% | 14.53% | 24.61% | 38.6% | 35.11% | 27.1% | 32.63% | 31.27% | 31.17% |
| Gross Profit Growth % | 17.23% | -5.83% | 3.4% | -51.38% | -1.14% | 0.33% | -28.36% | 49.54% | -3.71% | - |
| Operating Expenses | 67.68M | 64.75M | 75.53M | 65.26M | 47.76M | 50.86M | 49.78M | 50.69M | 57.54M | 42.21M |
| OpEx % of Revenue | 12.72% | 12.35% | 13.55% | 40.77% | 47.35% | 45.71% | 48.21% | 39.52% | 44.65% | - |
| Selling, General & Admin | 58.21M | 51.95M | 64.06M | 40.67M | 27.72M | 34.66M | 38.97M | 40.46M | 44.05M | 33.33M |
| SG&A % of Revenue | 10.94% | 9.91% | 11.49% | 25.41% | 27.48% | 31.15% | 37.74% | 31.55% | 34.18% | - |
| Research & Development | 9.47M | 12.8M | 11.47M | 7.58M | 6.68M | 7.84M | 8.74M | 8.57M | 8.26M | 7.58M |
| R&D % of Revenue | 1.78% | 2.44% | 2.06% | 4.74% | 6.63% | 7.04% | 8.46% | 6.69% | 6.41% | - |
| Other Operating Expenses | -333K | 0 | 0 | 17.01M | 13.36M | 8.36M | 2.08M | 1.66M | 5.24M | 0 |
| Operating Income | 15.51M▲ 0% | 11.85M▼ 23.6% | -8.01M▼ 167.6% | -25.88M▼ 223.0% | -8.82M▲ 65.9% | -11.79M▼ 33.6% | -21.8M▼ 84.9% | -8.84M▲ 59.4% | -17.25M▼ 95.0% | -78K▲ 0% |
| Operating Margin % | 2.91% | 2.26% | -1.44% | -16.17% | -8.75% | -10.6% | -21.11% | -6.9% | -13.38% | -0.06% |
| Operating Income Growth % | 178.36% | -23.59% | -167.61% | -223.05% | 65.9% | -33.64% | -84.85% | 59.42% | -94.99% | - |
| EBITDA | 26.18M | 23.82M | 6.59M | -7.04M | 11.04M | 6.27M | -8.62M | -844K | -9.22M | 7.38M |
| EBITDA Margin % | 4.92% | 4.54% | 1.18% | -4.4% | 10.95% | 5.63% | -8.35% | -0.66% | -7.15% | 5.46% |
| EBITDA Growth % | 344.26% | -9.03% | -72.33% | -206.8% | 256.92% | -43.23% | -237.46% | 90.21% | -992.18% | 161.18% |
| D&A (Non-Cash Add-back) | 10.68M | 11.97M | 14.6M | 18.84M | 19.87M | 18.06M | 13.18M | 8M | 8.03M | 7.46M |
| EBIT | 16M | 13.59M | 8.87M | -26M | -20.85M | -5.22M | -46.35M | 27.6M | -16.84M | -2.37M |
| Net Interest Income | -1.81M | -1.74M | -5.08M | -4.57M | -8.88M | -15.47M | -17.58M | -18.09M | -21.84M | -15.26M |
| Interest Income | 16K | 211K | 145K | 72K | 48K | 81K | 68K | 0 | 0 | 401K |
| Interest Expense | 1.83M | 1.95M | 5.23M | 4.65M | 8.93M | 15.55M | 17.65M | 18.09M | 21.84M | 15.08M |
| Other Income/Expense | -493K | 2.81M | -1.83M | -4.77M | -20.96M | -8.9M | -42.13M | 18.36M | -21.43M | -33.6M |
| Pretax Income | 15.01M▲ 0% | 16.4M▲ 9.2% | 3.64M▼ 77.8% | -30.64M▼ 941.9% | -29.79M▲ 2.8% | -20.69M▲ 30.6% | -63.93M▼ 209.0% | 9.51M▲ 114.9% | -38.67M▼ 506.5% | -33.67M▲ 0% |
| Pretax Margin % | 2.82% | 3.13% | 0.65% | -19.15% | -29.53% | -18.59% | -61.9% | 7.42% | -30.01% | -24.92% |
| Income Tax | 4.33M | -9.36M | 1.52M | -8.77M | -6.35M | -5.21M | 308K | 183K | 43K | 327K |
| Effective Tax Rate % | 28.88% | -57.1% | 41.7% | 28.63% | 21.32% | 25.19% | -0.48% | 1.92% | -0.11% | -0.97% |
| Net Income | 10.59M▲ 0% | 24.83M▲ 134.5% | 2.12M▼ 91.5% | -38.19M▼ 1899.8% | -32.29M▲ 15.4% | -116.72M▼ 261.4% | -99.56M▲ 14.7% | 12.01M▲ 112.1% | -38.72M▼ 422.3% | -34.09M▲ 0% |
| Net Margin % | 1.99% | 4.74% | 0.38% | -23.86% | -32.01% | -104.89% | -96.41% | 9.37% | -30.04% | -25.22% |
| Net Income Growth % | 190.97% | 134.46% | -91.45% | -1899.76% | 15.44% | -261.41% | 14.7% | 112.07% | -422.29% | 23.66% |
| Net Income (Continuing) | 10.13M | 25.76M | 2.12M | -21.87M | -23.44M | -15.48M | -64.24M | 9.33M | -38.72M | -34.09M |
| Discontinued Operations | 542K | 0 | 0 | -16.32M | -8.86M | -101.24M | -35.33M | 2.68M | 0 | 0 |
| Minority Interest | 1.54M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.38▲ 0% | 0.89▲ 134.2% | 0.07▼ 91.7% | -1.31▼ 1865.5% | -1.12▲ 14.5% | -3.97▼ 254.5% | -3.32▲ 16.4% | 0.33▲ 109.9% | -1.27▼ 484.8% | -0.91▲ 0% |
| EPS Growth % | 188.37% | 134.21% | -91.66% | -1865.5% | 14.5% | -254.46% | 16.37% | 109.94% | -484.85% | 30.72% |
| EPS (Basic) | 0.39 | 0.90 | 0.07 | -1.31 | -1.12 | -3.97 | -3.32 | 0.39 | -1.27 | - |
| Diluted Shares Outstanding | 27.65M | 27.91M | 28.61M | 29.16M | 29.29M | 29.47M | 29.96M | 36.66M | 34.82M | 37.48M |
| Basic Shares Outstanding | 27.5M | 27.7M | 28.36M | 29.16M | 29.29M | 29.47M | 29.96M | 30.47M | 34.82M | 37.48M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LFCR Balance Sheet
Lifecore Biomedical, Inc. (LFCR) balance sheet — assets, liabilities & shareholders' equity
| Line item | May'17 | May'18 | May'19 | May'20 | May'21 | May'22 | May'23 | May'24 | May'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 81.28M | 97.06M | 133.04M | 157.11M | 148.32M | 116.67M | 93.88M | 81.03M | 85.68M | 77.64M |
| Cash & Short-Term Investments | 5.41M | 2.9M | 1.08M | 360K | 1.16M | 991K | 19.09M | 8.46M | 8.27M | 20.8M |
| Cash Only | 5.41M | 2.9M | 1.08M | 360K | 1.16M | 991K | 19.09M | 8.46M | 8.27M | 20.8M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 45.9M | 53.88M | 69.56M | 76.21M | 41.43M | 38.31M | 29.02M | 31.15M | 43.67M | 26.89M |
| Days Sales Outstanding | 31.48 | 37.51 | 45.54 | 173.77 | 149.91 | 125.68 | 102.58 | 88.65 | 123.68 | 90.13 |
| Inventory | 25.29M | 31.82M | 54.13M | 66.31M | 63.08M | 36M | 40.84M | 39.98M | 32.29M | 28.16M |
| Days Inventory Outstanding | 20.56 | 26.05 | 41.46 | 200.56 | 371.71 | 181.98 | 198.01 | 168.87 | 133.07 | 120.98 |
| Other Current Assets | 2.27M | 3.21M | 0 | 0 | 37.62M | 34.31M | 4.92M | 1.44M | 1.45M | 1.8M |
| Total Non-Current Assets | 276.73M | 307.64M | 386.05M | 384.21M | 354.6M | 158.03M | 159.67M | 172.93M | 153.66M | 147.86M |
| Property, Plant & Equipment | 133.22M | 159.62M | 200.03M | 217.66M | 137.38M | 124.22M | 138.67M | 149.16M | 129.01M | 125.51M |
| Fixed Asset Turnover | 4.00x | 3.28x | 2.79x | 0.74x | 0.73x | 0.90x | 0.74x | 0.86x | 1.00x | 1.07x |
| Goodwill | 54.78M | 54.51M | 76.74M | 69.39M | 33.92M | 13.88M | 13.88M | 13.88M | 13.88M | 13.88M |
| Intangible Assets | 22.81M | 21.84M | 45.25M | 38.1M | 25.63M | 4.2M | 4.2M | 4.2M | 4.2M | 0 |
| Long-Term Investments | 63.6M | 66.5M | 61.1M | 56.9M | 45.1M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -5.51M | -581K | -9.74M | -25.3M | 112.57M | 15.73M | 2.92M | 5.68M | 6.58M | 29.11M |
| Total Assets | 358.01M▲ 0% | 404.7M▲ 13.0% | 519.09M▲ 28.3% | 541.31M▲ 4.3% | 502.92M▼ 7.1% | 274.7M▼ 45.4% | 253.54M▼ 7.7% | 253.96M▲ 0.2% | 239.34M▼ 5.8% | 225.5M▲ 0% |
| Asset Turnover | 1.49x | 1.30x | 1.07x | 0.30x | 0.20x | 0.41x | 0.41x | 0.51x | 0.54x | 0.58x |
| Asset Growth % | 4.23% | 13.04% | 28.26% | 4.28% | -7.09% | -45.38% | -7.7% | 0.16% | -5.76% | -24.68% |
| Total Current Liabilities | 51.45M | 88.38M | 137.09M | 164.39M | 101.89M | 176.58M | 39.29M | 38.87M | 30.18M | 20.5M |
| Accounts Payable | 24.53M | 34.67M | 53.97M | 51.65M | 16.3M | 12.95M | 22.1M | 16.33M | 8.22M | 6.64M |
| Days Payables Outstanding | 19.94 | 28.38 | 41.34 | 156.21 | 96.05 | 65.47 | 107.13 | 68.99 | 33.88 | 30.23 |
| Short-Term Debt | 7.94M | 31.94M | 61.79M | 88.95M | 29M | 138.18M | 580K | 943K | 3.44M | 1.34M |
| Deferred Revenue (Current) | 310K | 2.63M | 499K | 352K | 637K | 919K | 4.05M | 2.11M | 3.42M | 17.94M |
| Other Current Liabilities | 11.17M | 10.44M | 10.04M | 9.03M | 50.4M | 13.69M | 4.14M | 8.54M | 8.31M | 2.44M |
| Current Ratio | 1.58x | 1.10x | 0.97x | 0.96x | 1.46x | 0.66x | 2.39x | 2.08x | 2.84x | 2.84x |
| Quick Ratio | 1.09x | 0.74x | 0.58x | 0.55x | 0.84x | 0.46x | 1.35x | 1.06x | 1.77x | 1.77x |
| Cash Conversion Cycle | 32.1 | 35.18 | 45.66 | 218.13 | 425.58 | 242.19 | 193.46 | 188.53 | 222.88 | 180.89 |
| Total Non-Current Liabilities | 78.4M | 63.77M | 111.86M | 145.88M | 198.25M | 10.3M | 218.49M | 203.77M | 207.83M | 184.22M |
| Long-Term Debt | 42.3M | 37.36M | 87.67M | 101.36M | 164.9M | 97.58M | 101.06M | 123.72M | 127M | 142.14M |
| Capital Lease Obligations | 3.64M | 3.64M | 3.53M | 26.38M | 20.36M | 7.66M | 9.71M | 4.94M | 0 | 20.43M |
| Deferred Tax Liabilities | 24.58M | 17.48M | 19.39M | 13.59M | 6.14M | 126K | 380K | 543K | 0 | 0 |
| Other Non-Current Liabilities | 7.88M | 5.28M | 1.74M | 4.55M | 6.85M | -95.06M | 104.39M | 69.86M | 80.83M | 180.63M |
| Total Liabilities | 129.86M | 152.14M | 248.95M | 310.27M | 300.14M | 186.88M | 257.77M | 242.65M | 238.01M | 204.72M |
| Total Debt | 53.97M | 72.94M | 152.52M | 221.12M | 215.86M | 247.78M | 112.62M | 133.57M | 130.82M | 150.14M |
| Net Debt | 48.56M | 70.04M | 151.44M | 220.76M | 214.7M | 246.79M | 93.53M | 125.11M | 122.56M | 129.35M |
| Debt / Equity | 0.24x | 0.29x | 0.56x | 0.96x | 1.06x | 2.82x | - | 11.81x | 97.92x | 97.92x |
| Debt / EBITDA | 2.06x | 3.06x | 23.14x | - | 19.55x | 39.52x | - | - | - | 20.35x |
| Net Debt / EBITDA | 1.85x | 2.94x | 22.98x | - | 19.44x | 39.36x | - | - | - | 17.53x |
| Interest Coverage | 8.76x | 6.97x | 1.70x | -5.60x | -2.33x | -0.34x | -2.63x | 1.53x | -0.77x | -0.16x |
| Total Equity | 228.15M▲ 0% | 252.56M▲ 10.7% | 270.14M▲ 7.0% | 231.04M▼ 14.5% | 202.78M▼ 12.2% | 87.82M▼ 56.7% | -4.23M▼ 104.8% | 11.31M▲ 367.5% | 1.34M▼ 88.2% | 20.78M▲ 0% |
| Equity Growth % | 7.44% | 10.7% | 6.96% | -14.47% | -12.23% | -56.69% | -104.82% | 367.49% | -88.19% | 1898.57% |
| Book Value per Share | 8.25 | 9.05 | 9.44 | 7.92 | 6.92 | 2.98 | -0.14 | 0.31 | 0.04 | 0.55 |
| Total Shareholders' Equity | 226.61M | 252.56M | 270.14M | 231.04M | 202.78M | 87.82M | -4.23M | 11.31M | 1.34M | 20.78M |
| Common Stock | 27K | 28K | 29K | 29K | 29K | 30K | 30K | 31K | 37K | 37K |
| Retained Earnings | 84.47M | 109.3M | 109.71M | 71.25M | 38.58M | -78.97M | -178.54M | -166.52M | -205.24M | -238.18M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 432K | 1.15M | 64K | -2.81M | -1.36M | -586K | 0 | 0 | 0 | 0 |
| Minority Interest | 1.54M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LFCR Cash Flow Statement
Lifecore Biomedical, Inc. (LFCR) cash flow — operating, investing & free cash flow history
| Line item | May'17 | May'18 | May'19 | May'20 | May'21 | May'22 | May'23 | May'24 | May'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 29.33M | 19.78M | 16.02M | -17.04M | 16.47M | -22.59M | -17.44M | 257K | -206K | -206K |
| Operating CF Margin % | 5.51% | 3.77% | 2.87% | -10.65% | 16.33% | -20.3% | -16.89% | 0.2% | -0.16% | - |
| Operating CF Growth % | 34.63% | -32.56% | -19% | -206.37% | 196.66% | -237.17% | 22.8% | 101.47% | -180.16% | 818.71% |
| Net Income | 10.68M | 24.92M | 411K | -15.15M | -32.29M | -116.72M | -99.56M | 12.01M | -38.72M | -34.09M |
| Depreciation & Amortization | 10.68M | 12.41M | 15.23M | 18.84M | 19.87M | 18.06M | 13.18M | 7.95M | 8.03M | 9.76M |
| Stock-Based Compensation | 3.96M | 4.4M | 3.56M | 2.38K | 3.36M | 2.61M | 3.61M | 6.2M | 10.16M | 5.91M |
| Deferred Taxes | 2.51M | -7.22M | 910K | -5.44M | -7.87M | -6.83M | 357K | 163K | 0 | 33K |
| Other Non-Cash Items | 919K | -4.64M | -2.91M | 12.37M | 23.65M | 83.38M | 45.19M | -22.38M | 25.02M | 39.89M |
| Working Capital Changes | 584K | -10.1M | -1.18M | -27.66M | 9.76M | -3.1M | 19.79M | -3.7M | -4.7M | -4.13M |
| Change in Receivables | -336K | -7.31M | -8.86M | -6.64M | 5.78M | -6.14M | 10.82M | -2.39M | -2.26M | 8.8M |
| Change in Inventory | 855K | -6.53M | -10.93M | -12.18M | -2.82M | -2.18M | -14.81M | 862K | 7.69M | 6.44M |
| Change in Payables | -5.19M | 4.96M | 19.12M | -1.25M | -5.98M | 9.34M | 16.04M | -6.68M | -1.67M | 734K |
| Cash from Investing | -25.01M | -35.59M | -96.8M | -23.89M | -12.31M | 79.96M | -4.81M | -18.39M | -6.42M | 3.09M |
| Capital Expenditures | -22.59M | -33.59M | -44.73M | -26.69M | -25.22M | -29.94M | -21.48M | -18.39M | -13.41M | -6.91M |
| CapEx % of Revenue | 4.24% | 6.41% | 8.02% | 16.67% | 25% | 26.91% | 20.8% | 14.34% | 10.41% | - |
| Acquisitions | -2.5M | -4.11M | -59.87M | 2.43M | 0 | 73.5M | 16.67M | 0 | 7M | 10M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 81K | -2M | 545K | 364K | 12.91M | -8.7M | 0 | 0 | 0 | 0 |
| Cash from Financing | -8.8M | 13.29M | 79.03M | 40.02M | -3.42M | -57.02M | 39.7M | 7.51M | 6.42M | -5.09M |
| Debt Issued (Net) | -8.63M | 18.92M | 54.91M | 41.77M | 7.47M | -55.41M | 3.12M | 2.17M | -18.56M | -5.13M |
| Equity Issued (Net) | 706K | 56K | 327K | 30K | 0 | 0 | 42.9M | 0 | 23.85M | -8K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -874K | -5.69M | 23.79M | -1.79M | -10.89M | -1.61M | -6.32M | 5.34M | 1.13M | 51K |
| Net Change in Cash | -4.49M▲ 0% | -2.52M▲ 43.9% | -1.75M▲ 30.5% | -912K▲ 47.9% | 742K▲ 181.4% | 348K▼ 53.1% | 17.45M▲ 4913.8% | -10.63M▼ 160.9% | -197K▲ 98.1% | 3.42M▲ 0% |
| Free Cash Flow | 6.74M▲ 0% | -13.81M▼ 305.1% | -28.71M▼ 107.9% | -43.73M▼ 52.3% | -8.75M▲ 80.0% | -52.53M▼ 500.2% | -38.92M▲ 25.9% | -18.14M▲ 53.4% | -13.62M▲ 24.9% | 10.47M▲ 0% |
| FCF Margin % | 1.27% | -2.63% | -5.15% | -27.32% | -8.68% | -47.21% | -37.69% | -14.14% | -10.57% | 7.74% |
| FCF Growth % | 135.29% | -305.06% | -107.91% | -52.28% | 79.98% | -500.24% | 25.91% | 53.4% | 24.9% | 196.3% |
| FCF per Share | 0.24 | -0.49 | -1.00 | -1.50 | -0.30 | -1.78 | -1.30 | -0.49 | -0.39 | -0.39 |
| FCF Conversion (FCF/Net Income) | 2.77x | 0.80x | 7.55x | 0.45x | -0.51x | 0.19x | 0.18x | 0.02x | 0.01x | -0.31x |
| Interest Paid | 2.33M | 2.29M | 0 | 0 | 13.22M | 16.89M | 31.02M | 2.73M | 1.91M | 265K |
| Taxes Paid | 2.79M | 283K | 0 | 0 | 0 | 441K | 23K | 72K | 46K | 17K |
LFCR Key Ratios
Lifecore Biomedical, Inc. (LFCR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 4.81% | 10.33% | 0.81% | -15.24% | -14.89% | -80.33% | -238.21% | 339.11% | -612.08% | -146.68% |
| Return on Invested Capital (ROIC) | 4.3% | 2.97% | -1.61% | -4.44% | -1.52% | -2.35% | -7.71% | -5.88% | -9.94% | -9.94% |
| Gross Margin | 15.63% | 14.94% | 14.53% | 24.61% | 38.6% | 35.11% | 27.1% | 32.63% | 31.27% | 31.17% |
| Net Margin | 1.99% | 4.74% | 0.38% | -23.86% | -32.01% | -104.89% | -96.41% | 9.37% | -30.04% | -25.22% |
| Debt / Equity | 0.24x | 0.29x | 0.56x | 0.96x | 1.06x | 2.82x | - | 11.81x | 97.92x | 97.92x |
| Interest Coverage | 8.76x | 6.97x | 1.70x | -5.60x | -2.33x | -0.34x | -2.63x | 1.53x | -0.77x | -0.16x |
| FCF Conversion | 2.77x | 0.80x | 7.55x | 0.45x | -0.51x | 0.19x | 0.18x | 0.02x | 0.01x | -0.31x |
| Revenue Growth | -1.63% | -1.51% | 6.36% | -71.29% | -36.98% | 10.31% | -7.19% | 24.2% | 0.47% | 3.72% |
LFCR SEC Filings & Documents
Lifecore Biomedical, Inc. (LFCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
LFCR Frequently Asked Questions
Lifecore Biomedical, Inc. (LFCR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lifecore Biomedical, Inc. (LFCR) reported $135.2M in revenue for fiscal year 2025. This represents a 5306% increase from $2.5M in 1996.
Lifecore Biomedical, Inc. (LFCR) grew revenue by 0.5% over the past year. Growth has been modest.
Lifecore Biomedical, Inc. (LFCR) reported a net loss of $34.1M for fiscal year 2025.
Dividend & Returns
Lifecore Biomedical, Inc. (LFCR) has a return on equity (ROE) of -612.1%. Negative ROE indicates the company is unprofitable.
Lifecore Biomedical, Inc. (LFCR) generated $10.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More LFCR
Lifecore Biomedical, Inc. (LFCR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates